New drug combo shows promise for recurrent uterine cancer
NCT ID NCT05870761
First seen Nov 20, 2025 · Last updated May 07, 2026 · Updated 19 times
Summary
This early-phase trial tests whether combining two drugs—niraparib and dostarlimab—can shrink or control a rare, aggressive uterine cancer that has returned or not gone away. The study enrolled 8 adults who had already tried standard chemotherapy. The goal is to see how many patients respond and how long the benefit lasts.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT ENDOMETRIAL SEROUS ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
Conditions
Explore the condition pages connected to this study.